Lonza Expands Bioconjugation Capabilities in Switzerland

Lonza Group AG has announced an expansion of its bioconjugation facility in Visp, Switzerland. This development will include two new manufacturing suites, increasing the total manufacturing area by 2,000 square meters. The expansion aims to meet the rising market demand for bioconjugates, particularly as more antibody-drug conjugates (ADCs) approach commercialization. The suites are expected to be operational by 2028 and will create approximately 200 new jobs.

The expansion will double Lonza's multipurpose capacity, enhancing its ability to provide launch and commercial supply of bioconjugates. This investment follows a recent customer-dedicated expansion in Visp, supporting both early clinical development and large-scale manufacturing. The facility will also feature drug product filling capabilities.

Lonza's new suites will adhere to sustainability standards, incorporating energy-efficient systems to reduce emissions and improve liquid waste management, decreasing waste by up to 90%. With over 1,000 cGMP batches produced since 2006, Lonza continues to lead in offering integrated solutions in bioconjugation.